Blunted opiate modulation of hypothalamic-pituitary-adrenocortical activity in men and women who smoke.
OBJECTIVE
To examine the extent to which nicotine dependence alters endogenous opioid regulation of the hypothalamic-pituitary-adrenocortical (HPA) axis functions. Endogenous opiates play an important role in regulating mood, pain, and drug reward. They also regulate the HPA functions. Previous work has demonstrated an abnormal HPA response to psychological stress among dependent smokers.


METHODS
Smokers and nonsmokers (total n = 48 participants) completed two sessions during which a placebo or 50 mg of naltrexone was administered, using a double-blind design. Blood and saliva samples, cardiovascular and mood measures were obtained during a resting absorption period, after exposure to two noxious stimuli, and during an extended recovery period. Thermal pain threshold and tolerance were assessed in both sessions. Participants also rated pain during a 90-second cold pressor test.


RESULTS
Opioid blockade increased adrenocorticotropin, plasma cortisol, and salivary cortisol levels; these increases were enhanced by exposure to the noxious stimuli. These responses were blunted in smokers relative to nonsmokers. Smokers tended to report less pain than nonsmokers, and women reported more pain during both pain procedures, although sex differences in pain were significant only among nonsmokers.


CONCLUSIONS
We conclude that nicotine dependence is associated with attenuated opioid modulation of the HPA. This dysregulation may play a role in the previously observed blunted responses to stress among dependent smokers.
al'Absi
Mustafa
M
Department of Behavioral Sciences, University of Minnesota Medical School, Duluth, Minnesota 55812, USA. malabsi@umn.edu
Wittmers
Lorentz E
LE
Hatsukami
Dorothy
D
Westra
Ruth
R
D000324:Adrenocorticotropic Hormone / Q000097:blood; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D009271:Naltrexone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology*; D018847:Opioid Peptides / Q000502:physiology*; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000503:physiopathology; D012463:Saliva / Q000737:chemistry; D012737:Sex Factors; D013697:Thermosensing / Q000187:drug effects / Q000502:physiology; D014029:Tobacco Use Disorder / Q000503:physiopathology*; D055815:Young Adult
D009292:Narcotic Antagonists; D018847:Opioid Peptides; D009271:Naltrexone; D009538:Nicotine; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone
Eur J Pharmacol. 1993 Dec 1;248(4):333-5
8181540
Psychosom Med. 2006 Mar-Apr;68(2):299-306
16554397
Pain. 1987 Aug;30(2):191-197
3670870
Pain. 1991 Mar;44(3):255-262
2052394
Psychopharmacology (Berl). 1994 May;114(4):583-90
7855219
Horm Behav. 1991 Jun;25(2):217-28
2066081
Int J Psychophysiol. 1998 Nov;30(3):313-8
9834887
Psychosom Med. 1990 Sep-Oct;52(5):544-57
2247560
Neuroendocrinology. 1986;42(2):148-52
2936971
Neuropsychopharmacology. 2006 Jan;31(1):204-11
16123758
J Auton Nerv Syst. 1998 Mar 3;69(1):49-55
9672123
J Steroid Biochem Mol Biol. 1992 Dec;43(7):683-92
1472460
J Comp Neurol. 1990 Feb 22;292(4):651-67
2324319
J Endocrinol. 1994 Apr;141(1):163-8
8031419
Alcohol Clin Exp Res. 1998 Oct;22(7):1430-6
9802524
Int J Behav Med. 1994;1(3):264-83
16250801
Psychopharmacology (Berl). 1997 Apr;130(3):197-202
9151352
Physiol Behav. 1992 Oct;52(4):699-706
1329123
Psychosom Med. 1998 Jul-Aug;60(4):521-7
9710300
Pain. 2002 Mar;96(1-2):197-204
11932075
Clin Endocrinol Metab. 1983 Nov;12(3):597-618
6323065
J Affect Disord. 1999 Jun;53(3):263-8
10404712
Psychoneuroendocrinology. 2004 Jan;29(1):83-98
14575731
Am J Obstet Gynecol. 1990 Feb;162(2):502-14
2178432
Pain. 1989 May;37(2):143-160
2664663
J Clin Endocrinol Metab. 1998 Jun;83(6):2138-42
9626152
Neuroendocrinology. 1987 Sep;46(3):199-206
2821423
J Health Soc Behav. 1983 Dec;24(4):385-96
6668417
Eur J Endocrinol. 2002 Feb;146(2):231-5
11834433
Pharmacol Biochem Behav. 1993 Mar;44(3):527-31
8451256
Psychosom Med. 1994 May-Jun;56(3):245-50
8084971
Pain. 2005 Apr;114(3):372-385
15777863
Endocrine. 2001 Mar;14(2):221-4
11394640
Psychopharmacology (Berl). 2001 Dec;158(4):331-42
11797054
Pain. 1985 Sep;23(1):73-82
2865712
Pain. 1992 Feb;48(2):197-203
1589238
Br J Addict. 1991 Sep;86(9):1119-27
1932883
Life Sci. 1984 Jan 2;34(1):57-65
6319934
Pharmacol Biochem Behav. 2003 Jan;74(2):401-10
12479961
J Psychosom Res. 1980;24(3-4):125-30
7441580
Brain Res. 1999 Mar 20;822(1-2):107-13
10082888
Pharmacol Biochem Behav. 2000 Jul;66(3):563-72
10899371
JAMA. 1992 Mar 4;267(9):1244-52
1538563
Psychosom Med. 1996 Jul-Aug;58(4):326-32
8827795
Psychoneuroendocrinology. 1998 Feb;23(2):115-30
9621393
Psychopharmacology (Berl). 2005 Aug;181(1):107-17
15834539
Arch Gen Psychiatry. 1999 Jul;56(7):663-8
10401515
Psychosom Med. 1997 Sep-Oct;59(5):512-20
9316184
Psychophysiology. 1987 Jul;24(4):479-86
3615759
J Neurochem. 2006 Dec;99(5):1321-7
17064351
Hypertension. 1989 Dec;14(6):636-44
2555303
Pain. 1999 Nov;83(2):331-8
10534606
Neuropsychopharmacology. 2002 Jan;26(1):106-14
11751037